女性型脱发的临床进展

doi:10.3760/cma.j.issn.0412-4030.2017.10.025

摘要/Abstract

摘要： 女性型脱发（female pattern hair loss， FPHL）是成年女性脱发的主要原因，临床表现具有特征性，发病机制尚不完全清楚，可对患者生活质量造成影响［1］。最初，该病被泛称为女性弥漫性脱发。1942年，Hamilton证实了雄激素在男性型脱发（male pattern alopecia，MPA）中的作用后，开始使用雄激素性脱发这一术语，以强调激素和遗传因素的作用。由于女性弥漫性脱发曾被认为是与MPA为同一疾病的不同亚型，人们开始改称女性雄激素性脱发。尽管男女两型脱发的毛囊改变相似，但其临床表现和对抗雄激素治疗的反应有差异，而雄激素在女性型脱发中的致病作用尚未完全阐明，故FPHL的命名比女性雄激素性脱发更合适［2］……

张迎春吕中法朱健伟. 女性型脱发的临床进展[J]. 中华皮肤科杂志, 2017, 50(10): 770-773.doi:10.3760/cma.j.issn.0412-4030.2017.10.025

Ying-Chun ZHANG Jian-Wei ZHU. Female pattern hair loss in clinic[J]. Chinese Journal of Dermatology, 2017, 50(10): 770-773.doi:10.3760/cma.j.issn.0412-4030.2017.10.025

参考文献 32

［1］	Shapiro J. Clinical practice. Hair loss in women［J］. N Engl J Med, 2007, 357（16）: 1620⁃1630. DOI: 10.1056/NEJMcp072110.
［2］	Sinclair R. Winding the clock back on female androgenetic alopecia［J］. Br J Dermatol, 2012, 166（6）: 1157⁃1158. DOI: 10. 1111/j.1365⁃2133.2012.10934.x.
［3］	Wang TL, Zhou C, Shen YW, et al. Prevalence of androgenetic alopecia in China: a community⁃based study in six cities［J］. Br J Dermatol, 2010, 162（4）: 843⁃847. DOI: 10.1111/j.1365⁃2133. 2010.09640.x.
［4］	Su LH, Chen LS, Chen HH. Factors associated with female pattern hair loss and its prevalence in Taiwanese women: a community⁃based survey［J］. J Am Acad Dermatol, 2013, 69（2）: e69⁃77. DOI: 10.1016/j.jaad.2012.09.046.
［5］	Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome［J］. Am J Clin Dermatol, 2007, 8（4）: 201⁃219. DOI: 10.2165/00128071⁃200708040⁃00003.
［6］	Kim BJ, Kim JY, Eun HC, et al. Androgenetic alopecia in adolescents: a report of 43 cases［J］. J Dermatol, 2006, 33（10）: 696⁃699. DOI: 10.1111/j.1346⁃8138.2006.00161.x.
［7］	Madnani N, Khan K, Chauhan P, et al. Polycystic ovarian syndrome［J］. Indian J Dermatol Venereol Leprol, 2013, 79（3）: 310⁃321. DOI: 10.4103/0378⁃6323.110759.
［8］	Dalamaga M, Papadavid E, Basios G, et al. Ovarian SAHA syndrome is associated with a more insulin⁃resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study［J］. J Am Acad Dermatol, 2013, 69（6）: 922⁃930. DOI: 10.1016/j.jaad.2013.09.014.
［9］	Arias⁃Santiago S, Gutiérrez⁃Salmerón MT, Buendía⁃Eisman A, et al. Sex hormone⁃binding globulin and risk of hyperglycemia in patients with androgenetic alopecia［J］. J Am Acad Dermatol, 2011, 65（1）: 48⁃53. DOI: 10.1016/j.jaad.2010.05.002.
［10］	Su LH, Chen LS, Lin SC, et al. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease［J］. JAMA Dermatol, 2013, 149（5）: 601⁃606. DOI: 10.1001/jamadermatol.2013.130.
［11］	Yi SM, Son SW, Lee KG, et al. Gender⁃specific association of androgenetic alopecia with metabolic syndrome in a middle⁃aged Korean population［J］. Br J Dermatol, 2012, 167（2）: 306⁃313. DOI: 10.1111/j.1365⁃2133.2012.10978.x.
［12］	Abdel FNS, Darwish YW. Androgenetic alopecia and insulin resistance: are they truly associated?［J］. Int J Dermatol, 2011, 50（4）: 417⁃422. DOI: 10.1111/j.1365⁃4632.2010.04677.x.
［13］	Mahé YF, Michelet JF, Billoni N, et al. Androgenetic alopecia and microinflammation［J］. Int J Dermatol, 2000, 39（8）: 576⁃584. DOI: 10.1046/j.1365⁃4362.2000.00612.x
［14］	Stefanato CM. Histopathology of alopecia: a clinicopathological approach to diagnosis［J］. Histopathology, 2010, 56（1）: 24⁃38. DOI: 10.1111/j.1365⁃2559.2009.03439.x.
［15］	Yazdan P. Update on the genetics of androgenetic alopecia, female pattern hair loss, and alopecia areata: implications for molecular diagnostic testing［J］. Semin Cutan Med Surg, 2012, 31（4）: 258⁃266. DOI: 10.1016/j.sder.2012.08.003.
［16］	Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness［J］. J Invest Dermatol, 2001, 116（3）: 452⁃455. DOI: 10.1046/j.1523⁃1747.2001.01261.x.
［17］	Li R, Brockschmidt FF, Kiefer AK, et al. Six novel susceptibility Loci for early⁃onset androgenetic alopecia and their unexpected association with common diseases［J］. PLoS Genet, 2012, 8（5）:e1002746. DOI: 10.1371/journal.pgen.1002746.
［18］	Redler S, Dobson K, Drichel D, et al. Investigation of six novel susceptibility loci for male androgenetic alopecia in women with female pattern hair loss［J］. J Dermatol Sci, 2013, 72（2）: 186⁃188. DOI: 10.1016/j.jdermsci.2013.06.012.
［19］	Heilmann S, Kiefer AK, Fricker N, et al. Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology［J］. J Invest Dermatol, 2013, 133（6）: 1489⁃1496. DOI: 10.1038/jid.2013.43.
［20］	Nuwaihyd R, Redler S, Heilmann S, et al. Investigation of four novel male androgenetic alopecia susceptibility loci: no association with female pattern hair loss［J］. Arch Dermatol Res, 2014, 306（4）: 413⁃418. DOI: 10.1007/s00403⁃013⁃1436⁃4.
［21］	Gatherwright J, Liu MT, Gliniak C, et al. The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins［J］. Plast Reconstr Surg, 2012, 130（6）: 1219⁃1226. DOI: 10.1097/PRS.0b013e31826d104f.
［22］	Blume⁃Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents［J］. Br J Dermatol, 2011, 164（1）: 5⁃15. DOI: 10.1111/j.1365⁃2133.2010.10011.x.
［23］	Lee WS, Oh Y, Ji JH, et al. Analysis of familial factors using the basic and specific （BASP） classification in Korean patients with androgenetic alopecia［J］. J Am Acad Dermatol, 2011, 65（1）: 40⁃47. DOI: 10.1016/j.jaad.2010.05.005.
［24］	Lee WS, Lee HJ, Choi GS, et al. Guidelines for management of androgenetic alopecia based on BASP classification⁃⁃the Asian Consensus Committee guideline［J］. J Eur Acad Dermatol Venereol, 2013, 27（8）: 1026⁃1034. DOI: 10.1111/jdv.12034.
［25］	Gassmueller J, Rowold E, Frase T, et al. Validation of TrichoScan technology as a fully⁃automated tool for evaluation of hair growth parameters［J］. Eur J Dermatol, 2009, 19（3）: 224⁃231. DOI: 10. 1684/ejd.2009.0640.
［26］	Rasheed H, Mahgoub D, Hegazy R, et al. Serum ferritin and vitamin d in female hair loss: do they play a role?［J］. Skin Pharmacol Physiol, 2013, 26（2）: 101⁃107. DOI: 10.1159/000346698.
［27］	Kantor J, Kessler LJ, Brooks DG, et al. Decreased serum ferritin is associated with alopecia in women［J］. J Invest Dermatol, 2003, 121（5）: 985⁃988. DOI: 10.1046/j.1523⁃1747.2003.12540.x.
［28］	Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia［J］. Mol Cell Endocrinol, 2011, 347（1⁃2）: 90⁃96. DOI: 10.1016/j.mce.2011.05.045.
［29］	Rebora A, Guarrera M. Kenogen. A new phase of the hair cycle?［J］. Dermatology, 2002, 205（2）: 108⁃110. DOI: 10.1159/000063908.
［30］	Sawaya ME, Blume⁃Peytavi U, Mullins DL, et al. Effects of finasteride on apoptosis and regulation of the human hair cycle［J］. J Cutan Med Surg, 2002, 6（1）: 1⁃9. DOI: 10.1007/s10227⁃001⁃0024⁃y.
［31］	Reid EE, Haley AC, Borovicka JH, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia［J］. J Am Acad Dermatol, 2012, 66（3）: e97⁃102. DOI: 10.1016/j.jaad.2010.11. 042.
［32］	Gupta AK, Daigle D. The use of low⁃level light therapy in the treatment of androgenetic alopecia and female pattern hair loss［J］. J Dermatolog Treat, 2014, 25（2）: 162⁃163. DOI: 10.3109/09546634.2013.832134.